Paris, November 30, 2010 – Cellectis (Alternext: ALCLS), the French genome engineering specialist, will today host an R&D day for investors, analysts and the media at its headquarters, near Paris.
Following a tour of its proprietary meganuclease technical platform, members of Cellectis’ management and scientific teams will detail the activities within its core business areas including: meganuclease engineering technology, research tools, genome engineering in plants and therapeutic programs. Guest speaker, Dr Serge Braun from the French Muscular Dystrophy Association (AFM), will provide an update on its collaboration with Cellectis in therapeutics. Finally, the potential applications of induced pluripotent stem cell (iPS) technologies, recently licensed from Academia Japan, will also be described.
Registration will commence at 11.00AM CET and presentations will be available shortly after the event at www.cellectis.com/investors/accounts-and-reports.